ABOS NASDAQ
Acumen Pharmaceuticals, Inc.
1W: +11.9%
1M: -1.7%
3M: +7.1%
YTD: +11.9%
1Y: +2.3%
3Y: -34.7%
5Y: -83.7%
$2.26
-0.01 (-0.44%)
After Hours: $2.28 (+0.02, +0.66%)
Weekly Expected Move ±11.7%
$2
$2
$2
$2
$2
Credit Risk of going bust: higher than 79% of companies Debt: 13.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $164.2M.
Distance to default 2.66 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.9%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $164.2M.
Distance to default 2.66 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.9%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$163.4M
52W Range1.5-3.6
Volume1,797,074
Avg Volume518,050
Beta0.33
Dividend—
Analyst Ratings
Company Info
CEODaniel J. O'Connell
Employees61
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-01
Websiteacumenpharm.com
1210-1220 Washington St.
Newton, MA 02465
US
Newton, MA 02465
US
434 297 1000
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Latest News
At a glance: stocks gapping up premarket
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
Acumen targets 30% iADRS slowing as Phase II ALTITUDE-AD data due in November
Acumen Pharmaceuticals GAAP EPS of -$0.35 beats by $0.02
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Has Average Price Target of $7.00 According to Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Porter Derrell | M-Exempt | 13,040 | $1.07 | 2026-06-17 |
| Porter Derrell | S-Sale | 13,040 | $2.33 | 2026-06-17 |
| Porter Derrell | M-Exempt | 13,040 | $1.07 | 2026-06-17 |
| Porter Derrell | S-Sale | 12,800 | $2.33 | 2026-06-16 |
| Porter Derrell | M-Exempt | 6,460 | $1.07 | 2026-06-15 |